Phathom Pharmaceuticals to Present at 40th Annual Cowen and Company Health Care Conference on March 2, 2020
February 25, 2020
Phathom Pharmaceuticals to Present at 40th Annual Cowen and Company Health Care Conference on March 2, 2020 FLORHAM PARK, NJ.–Feb. 25, 2020– Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced that Terrie Curran, President and Chief Executive…
Phathom Pharmaceuticals Announces Leadership Succession Plan and Strengthens Board of Directors with New Appointments
September 27, 2019
Terrie Curran, President, Global Inflammation and Immunology Franchise at Celgene Corporation, to succeed David Socks as CEO Michael Cola, Terrie Curran, Heidi Kunz, and Chris Slavinsky appointed to Board of Directors BUFFALO GROVE, ILLINOIS, September 27, 2019 – Phathom Pharmaceuticals, Inc., a biopharmaceutical company focused on the…
Phathom Pharmaceuticals to Present at Jefferies 2019 Healthcare Conference
June 4, 2019
Menlo Park, Calif., June 4, 2019 – Phathom Pharmaceuticals, a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal (GI) diseases and disorders, today announced that David Socks, Chief Executive Officer, will present at the Jefferies 2019 Healthcare Conference on Thursday, June 6, 2019…
Takeda and Frazier Healthcare Partners Announce Collaboration to Launch Phathom Pharmaceuticals
May 15, 2019
New Company and Collaboration To Develop Novel Therapeutics Including Vonoprazan for the Treatment of Acid-Related Disorders in North America and Europe Cambridge, Mass. and Menlo Park, Calif., May 15, 2019 – Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) and Frazier Healthcare Partners (“Frazier”) today announced a collaboration to…
Media inquiries: If you are a reporter with questions about Phathom Pharmaceuticals, or if you would like to request an interview, please contact: info@phathompharma.com